A U-->G mutation in the polypyrimidine tract of the human beta-globin gene reduces splicing efficiency, likely due to increased interaction with hnRNP C protein, contributing to the pathogenesis of beta-thalassemia intermedia.
Answers are grounded in this paper and cite their sources.
May support hnRNP C-targeted splicing therapies in beta-thalassemia; leaves open clinical translation from animal models.
In a patient with a beta-thalassemia intermedia, a mutation was identified in the second intron of the human beta-globin gene. The U-->G mutation is located within the polypyrimidine tract at position -8 upstream of the 3' splice site. In vivo, this mutation leads to decreased levels of the hemoglobin protein. Because of the location of the mutation and the role of the polypyrimidine tract in the splicing process, we performed in vitro splicing assays on the pre-messenger RNA (pre-mRNA). We found that the splicing efficiency of the mutant pre-mRNA is reduced compared to the wild type and that no cryptic splice sites are activated. Analysis of splicing complex formation shows that the U-->G mutation affects predominantly the progression of the H complex towards the pre-spliceosome complex. By cross-linking and immunoprecipitation assays, we show that the hnRNP C protein interacts more efficiently with the mutant precursor than with the wild-type. This stronger interaction could play a role, directly or indirectly, in the decreased splicing efficiency.
No takes yet. Share an insight, caveat, or question.
Sébillon et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: